<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Primary <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (PCNSL) is a very uncommon disease in children, and usually treated by chemotherapy, combined with focal or craniospinal radiotherapy (RT) </plain></SENT>
<SENT sid="1" pm="."><plain>However, adverse effects of RT are a concern </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated the outcomes of childhood PCNSL, treated with systemic and intrathecal chemotherapy, but without RT </plain></SENT>
<SENT sid="3" pm="."><plain>For fifteen years, six patients among 175 of non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were diagnosed as PCNSL in Seoul National University Children's Hospital and we analyzed their medical records retrospectively </plain></SENT>
<SENT sid="4" pm="."><plain>Their male:female ratio was 5:1, and median age was 10.1 yr </plain></SENT>
<SENT sid="5" pm="."><plain>The primary sites were the sellar area in three patients, parietal area in one, cerebellum in one, and multiple areas in one </plain></SENT>
<SENT sid="6" pm="."><plain>Their <z:e sem="disease" ids="C1513672" disease_type="Disease or Syndrome" abbrv="">pathologic diagnoses</z:e> were diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in three patients, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in two, and undifferentiated B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in one </plain></SENT>
<SENT sid="7" pm="."><plain>Five were treated with the LMB96 treatment protocol, and one was treated with the CCG-106B protocol </plain></SENT>
<SENT sid="8" pm="."><plain>None had RT as a first-line treatment </plain></SENT>
<SENT sid="9" pm="."><plain>One patient had a local relapse and received RT and salvage chemotherapy, without success </plain></SENT>
<SENT sid="10" pm="."><plain>No patient had treatment-related mortality </plain></SENT>
<SENT sid="11" pm="."><plain>Their estimated 5-yr event-free and overall survival rates were both 83.3% </plain></SENT>
<SENT sid="12" pm="."><plain>In conclusion, PCNSL is a <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e> in childhood, but successfully treated by chemotherapy without RT </plain></SENT>
</text></document>